Clinical trial registry changes: March 2026

Among the trials TrialRedline tracks, 68 changed their ClinicalTrials.gov record in March 2026: 5 status changes to terminated, withdrawn or suspended, 12 primary outcome text edits, 12 completion dates moved later, 5 completion dates moved earlier, 17 enrollment changes, 35 other status changes. Each entry shows the previous and updated value and links to the registry's own version comparison.

68Trials with a recorded change
69Registry updates
60Sponsors

Trials terminated, withdrawn or suspended

5 in March 2026. Recruitment status changed to Terminated, Withdrawn or Suspended. Terminated first, then newest.

Primary outcome text edits

12 in March 2026. The text of the main study measures changed. Edits to capitalization, punctuation or spacing alone are left out. Newest first.

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Cohort 1-3: Proportion of IgAN, LN, MN, C3 Glomerulopathy subjects with treatment related adverse events (AE). Measure: Cohort 4: Proportion of IgAN patients of Asian descent with treatment related AEs. Measure: Cohort 4: Change from baseline in serum and urine complement component levels.. After: Measure: Cohort 1-3: Proportion of IgAN, LN, MN, C3 Glomerulopathy Participants With Treatment Related Adverse Events (AE). Measure: Cohort 4: Proportion of IgAN Participants of Asian Descent With Treatment Related AEs. Measure: Cohort 4: Change From Baseline in Serum and Urine Complement Component Levels..

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Percent Change From Baseline to Week 24 in the Number of Observable Motor Seizures per 28 Days. After: Measure: Percent Change From Baseline to Week 24 in the Number of Observable Motor Seizures Per 28 Days During the Double-blind Period.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Percent Change from Baseline in Fasting Triglycerides (TG) at Week 24. After: Measure: Percent Change From Baseline at Week 24 in Fasting Triglycerides (TG).

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Infection rate as measured by the proportion of subjects with abdominal incisional infection event. After: Measure: The Combined Infection and Mortality Rate Within 30 Days Post Index Surgery.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Clinical Endpoint. After: Measure: Surrogate / Intermediate Efficacy Endpoint -eGFR Slope Measure: Clinical Endpoint.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Percent Change From Baseline at Month 6 (average of Weeks 25 and 27) in Fasting Triglycerides (TG). After: Measure: Percent Change From Baseline in Fasting TG at Month 6.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Proportion of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear). After: Measure: Percentage of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear).

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence of complete debridement, clinically (visually) assessed after each application Measure: Incidence of complete wound closure. After: Measure: Incidence of complete debridement, clinically (visually) assessed after each application Measure: Facilitation of wound closure, clinically assessed, as measured by time to complete wound closure.

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Number of New Surgically Eligible BCCs (nSEBs). After: Measure: Number of Participants With New Surgically Eligible Basal Cell Carcinomas (nSEBs).

Check registry source

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Number of participants with change in functional vision in the study eye of RP subjects as assessed by LDNA Measure: Number of participants with change in functional vision in the study eye in Gene Agnostic group as assessed by LDNA. After: Measure: Change in functional vision from baseline to week 52 in pooled analysis when study eyes in treatment group were compared to study eyes in untreated control.

Check registry source

Completion dates moved later

12 in March 2026. Primary completion date moved later while its type (estimated or actual) stayed the same. Largest move first.

Completion dates moved earlier

5 in March 2026. Primary completion date moved earlier while its type stayed the same. Largest move first.

Enrollment changes

17 in March 2026. The participant count changed. Planned and actual counts are shown as recorded. Newest first.

Other recruitment status changes

35 in March 2026. Any other change of recruitment status, such as recruiting to completed. Newest first.

Showing 25 of 35. Browse all tracked trials to open the rest.

Cite this report

TrialRedline, “Clinical trial registry changes: March 2026”. https://trialredline.com/reports/2026-03

Based on public ClinicalTrials.gov record history. How we collect and check the data